Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sienna Biopharmaceuticals, Inc.SNNA · Entity 154554 | Director | May 30, 2019 | June 03, 2019 |
| Tyra Biosciences, Inc.TYRA · Entity 4680 | Director · President and CEO | September 15, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sienna Biopharmaceuticals, Inc.
Report date May 30, 2019 · Filed June 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2029-05-30 | Direct | 25,000 |
Reported balance
After 2019-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-30 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date.
Tyra Biosciences, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,438,495 |
Reported balance
After 2026-09-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-15 · Grant · Acquired 864 · Balance 1,438,495 F1: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. F2: Includes restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.
F2: Includes restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 17, 2026 23:29 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantCommon Stock | 864 | $9.13 | $7,887.46 |
DisclosureSEC source: 0001193125-26-394738 · ownership.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,438,495 F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. F2 · balance_after: Includes restricted stock units. Read SEC document |
| May 05, 2026 Filed May 7, 2026 20:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 265,000 | $0.00 Strike: $33.93 | $0.00 |
DisclosureSEC source: 0001193125-26-212114 · ownership.xml · derivative · entry 2 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,000 Underlying: Common Stock · 265,000 shares Expires 2036-05-04 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| May 05, 2026 Filed May 7, 2026 20:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantCommon Stock | 79,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-212114 · ownership.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,437,631 F1 · shares: Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · balance_after: Includes RSUs. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 20:54 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantCommon Stock | 1,463 | $9.13 | $13,355.73 |
DisclosureSEC source: 0001193125-26-111083 · ownership.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,358,631 F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| August 07, 2025 Filed Aug 7, 2025 20:36 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 570,000 | $0.00 Strike: $10.75 | $0.00 |
DisclosureSEC source: 0000950170-25-105128 · ownership.xml · derivative · entry 1 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 570,000 Underlying: Common Stock · 570,000 shares Expires 2035-08-06 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following August 7, 2025, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 22:44 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantCommon Stock | 1,241 | $9.78 | $12,130.78 |
DisclosureSEC source: 0000950170-25-041551 · ownership.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,357,168 F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| October 21, 2024 Filed Oct 22, 2024 21:13 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 13,188 | $28.16 | $371,370.12 |
DisclosureSEC source: 0000950170-24-116345 · ownership.xml · nonDerivative · entry 3 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,355,927 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $27.8957 to $28.5951. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| October 21, 2024 Filed Oct 22, 2024 21:13 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 5,896 | $27.32 | $161,081.08 |
DisclosureSEC source: 0000950170-24-116345 · ownership.xml · nonDerivative · entry 2 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,369,115 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $26.89 to $27.84. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 21:13 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 43,636 | $27.01 | $1,178,795.99 |
DisclosureSEC source: 0000950170-24-116345 · ownership.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,375,011 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $26.60 to $27.51. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 00:12 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 200 | $26.37 | $5,274.00 |
DisclosureSEC source: 0000950170-24-115432 · ownership.xml · nonDerivative · entry 6 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,418,647 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 00:12 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 15,194 | $25.84 | $392,597.77 |
DisclosureSEC source: 0000950170-24-115432 · ownership.xml · nonDerivative · entry 5 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,418,847 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F6 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $25.30 to $26.16. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 00:12 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 3,922 | $26.98 | $105,811.25 |
DisclosureSEC source: 0000950170-24-115432 · ownership.xml · nonDerivative · entry 4 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,434,041 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $26.79 to $27.08. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 00:12 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 24,475 | $26.23 | $642,062.47 |
DisclosureSEC source: 0000950170-24-115432 · ownership.xml · nonDerivative · entry 3 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,437,963 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $25.78 to $26.78. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 00:12 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 4,900 | $25.22 | $123,555.95 |
DisclosureSEC source: 0000950170-24-115432 · ownership.xml · nonDerivative · entry 2 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,462,438 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $24.72 to $25.59. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| October 15, 2024 Filed Oct 18, 2024 00:12 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 10,035 | $24.31 | $243,969.92 |
DisclosureSEC source: 0000950170-24-115432 · ownership.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,467,338 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $24.00 to $24.8667. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 21:38 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 500 | $24.00 | $12,000.00 |
DisclosureSEC source: 0000950170-24-111702 · ownership.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,477,373 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. Read SEC document |
| September 25, 2024 Filed Sep 25, 2024 22:44 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 600 | $24.01 | $14,406.00 |
DisclosureSEC source: 0000950170-24-109410 · ownership.xml · nonDerivative · entry 3 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,477,873 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $24.00 to $24.06. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| September 24, 2024 Filed Sep 25, 2024 22:44 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 1,055 | $24.02 | $25,340.68 |
DisclosureSEC source: 0000950170-24-109410 · ownership.xml · nonDerivative · entry 2 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,478,473 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $24.00 to $24.14. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 22:44 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 10,092 | $24.13 | $243,476.56 |
DisclosureSEC source: 0000950170-24-109410 · ownership.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,479,528 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $24.005 to $24.25. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| September 20, 2024 Filed Sep 20, 2024 22:24 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 7,109 | $24.19 | $171,950.36 |
DisclosureSEC source: 0000950170-24-108533 · ownership.xml · nonDerivative · entry 4 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,489,620 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $24.00 to $24.8963. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 22:24 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 27 | $25.10 | $677.62 |
DisclosureSEC source: 0000950170-24-108533 · ownership.xml · nonDerivative · entry 3 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,496,729 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 22:24 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 5,671 | $24.30 | $137,813.24 |
DisclosureSEC source: 0000950170-24-108533 · ownership.xml · nonDerivative · entry 2 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,496,756 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold within a one dollar price range. The actual sale prices range between $24.00 to $24.9749. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 22:24 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 3,500 | $24.00 | $84,000.00 |
DisclosureSEC source: 0000950170-24-108533 · ownership.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,502,427 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. Read SEC document |
| September 13, 2024 Filed Sep 17, 2024 21:15 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantCommon Stock | 1,350 | $6.58 | $8,881.65 |
DisclosureSEC source: 0000950170-24-107399 · ownership.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,505,927 F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 21:50 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 390,000 | $0.00 Strike: $21.57 | $0.00 |
DisclosureSEC source: 0000950170-24-098175 · ownership.xml · derivative · entry 1 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,000 Underlying: Common Stock · 390,000 shares Expires 2034-08-13 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following August 14, 2024, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:38 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantCommon Stock | 1,880 | $6.58 | $12,368.52 |
DisclosureSEC source: 0000950170-24-033814 · ownership.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,504,577 F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 01:22 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 13,817 | $16.97 | $234,430.28 |
DisclosureSEC source: 0000950170-24-011879 · ownership.xml · nonDerivative · entry 3 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,502,697 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.51 to $17.32. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| February 02, 2024 Filed Feb 7, 2024 01:22 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 7,187 | $17.04 | $122,494.51 |
DisclosureSEC source: 0000950170-24-011879 · ownership.xml · nonDerivative · entry 2 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,516,514 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $17.00 to $17.16. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| February 02, 2024 Filed Feb 7, 2024 01:22 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 78,996 | $16.45 | $1,299,160.32 |
DisclosureSEC source: 0000950170-24-011879 · ownership.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,523,701 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.9995. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 23:36 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantCommon Stock | 1,421 | $6.58 | $9,348.76 |
DisclosureSEC source: 0001209191-23-050092 · doc4.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,602,697 F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| July 28, 2023 Filed Aug 1, 2023 21:38 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 330,000 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001209191-23-044044 · doc4.xml · derivative · entry 1 Harris Todd · CIK 0001711463 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 330,000 shares Expires 2033-07-27 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following July 28, 2023, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 23:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 6,481 | $17.51 | $113,463.52 |
DisclosureSEC source: 0001209191-23-039807 · doc4.xml · nonDerivative · entry 4 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,601,276 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F5 · price: Represents the weighted average sale price for the entire number of shares sold within a one dollar price range. The actual sale prices range between $17.41 to $17.75. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 23:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 14,231 | $16.78 | $238,797.60 |
DisclosureSEC source: 0001209191-23-039807 · doc4.xml · nonDerivative · entry 3 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,607,757 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F4 · price: Represents the weighted average sale price for the entire number of shares sold within a one dollar price range. The actual sale prices range between $16.335 to $17.195. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 23:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 500 | $17.39 | $8,693.00 |
DisclosureSEC source: 0001209191-23-039807 · doc4.xml · nonDerivative · entry 2 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,621,988 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F3 · price: Represents the weighted average sale price for the entire number of shares sold within a one dollar price range. The actual sale prices range between $17.35 to $17.42. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 23:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 2,978 | $16.98 | $50,558.10 |
DisclosureSEC source: 0001209191-23-039807 · doc4.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,622,488 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold within a one dollar price range. The actual sale prices range between $16.29 to $17.29. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 21, 2023 Filed Jun 22, 2023 00:16 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 1,100 | $18.18 | $19,998.99 |
DisclosureSEC source: 0001209191-23-038945 · doc4.xml · nonDerivative · entry 7 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,625,466 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F8 · price: Represents the weighted average sale price for the entire number of shares sold within a one dollar price range. The actual sale prices range between $18.11 to $18.395. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 21, 2023 Filed Jun 22, 2023 00:16 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 14,027 | $17.71 | $248,357.85 |
DisclosureSEC source: 0001209191-23-038945 · doc4.xml · nonDerivative · entry 6 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,626,566 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F7 · price: Represents the weighted average sale price for the entire number of shares sold within a one dollar price range. The actual sale prices range between $17.075 to $18.035. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 21, 2023 Filed Jun 22, 2023 00:16 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 4,629 | $16.12 | $74,614.85 |
DisclosureSEC source: 0001209191-23-038945 · doc4.xml · nonDerivative · entry 5 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,640,593 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F6 · price: Represents the weighted average sale price for the entire number of shares sold within a one dollar price range. The actual sale prices range between $16.00 to $16.905. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 00:16 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 1,300 | $16.53 | $21,493.29 |
DisclosureSEC source: 0001209191-23-038945 · doc4.xml · nonDerivative · entry 4 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,645,222 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F5 · price: Represents the weighted average sale price for the entire number of shares sold within a one dollar price range. The actual sale prices range between $16.04 to $16.82. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 16, 2023 Filed Jun 22, 2023 00:16 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 600 | $18.50 | $11,100.00 |
DisclosureSEC source: 0001209191-23-038945 · doc4.xml · nonDerivative · entry 3 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,646,522 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F4 · price: Represents the weighted average sale price for the entire number of shares sold within a one dollar price range. The actual sale prices range between $18.00 to $19.00. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 16, 2023 Filed Jun 22, 2023 00:16 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 50,838 | $17.06 | $867,296.28 |
DisclosureSEC source: 0001209191-23-038945 · doc4.xml · nonDerivative · entry 2 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,647,122 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F3 · price: Represents the weighted average sale price for the entire number of shares sold within a one dollar price range. The actual sale prices range between $17.00 to $17.98. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 16, 2023 Filed Jun 22, 2023 00:16 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 3,316 | $16.49 | $54,680.84 |
DisclosureSEC source: 0001209191-23-038945 · doc4.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,697,960 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold within a one dollar price range. The actual sale prices range between $16.00 to $16.97. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 01:00 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,773 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001209191-23-037613 · doc4.xml · derivative · entry 6 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 376,837 Underlying: Common Stock · 12,773 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 01:00 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 12,773 | $16.13 | $205,996.56 |
DisclosureSEC source: 0001209191-23-037613 · doc4.xml · nonDerivative · entry 4 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,701,276 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.60. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 01:00 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 12,773 | $2.25 | $28,739.25 |
DisclosureSEC source: 0001209191-23-037613 · doc4.xml · nonDerivative · entry 3 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,714,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 01:00 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,927 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001209191-23-037613 · doc4.xml · derivative · entry 5 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 389,610 Underlying: Common Stock · 7,927 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 01:00 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 7,927 | $16.00 | $126,870.05 |
DisclosureSEC source: 0001209191-23-037613 · doc4.xml · nonDerivative · entry 2 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,701,276 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.05. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 01:00 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 7,927 | $2.25 | $17,835.75 |
DisclosureSEC source: 0001209191-23-037613 · doc4.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,709,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 21:20 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001209191-23-023402 · doc4.xml · derivative · entry 3 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 397,537 Underlying: Common Stock · 2,000 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 21:20 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 2,000 | $16.13 | $32,252.00 |
DisclosureSEC source: 0001209191-23-023402 · doc4.xml · nonDerivative · entry 2 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,701,276 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 and $16.240. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.